Previous Close | 0.5000 |
Open | 0.4840 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's Range | 0.4660 - 0.5022 |
52 Week Range | 0.4190 - 1.1400 |
Volume | |
Avg. Volume | 4,903 |
Market Cap | 25.602M |
Beta (5Y Monthly) | -0.05 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.4130 |
Earnings Date | Aug 15, 2022 - Aug 19, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 4.49 |
Subscribe to Yahoo Finance Plus to view Fair Value for ATBPF
By David Bautz, PhD OTC:ATBPF | TSX:ATE.TO READ THE FULL ATE.TO RESEARCH REPORT Business Update Phase 2 Post-Operative Pain Program to Initiate in Calendar 4Q22 Antibe Therapeutics, Inc. (OTC:ATBPF) (TSX:ATE.TO) is developing otenaproxesul as a solution to the dose-related gastrointestinal (GI) side effects associated with non-steroidal anti-inflammatory drugs (NSAIDs). It uses naproxen as a base
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
TORONTO, June 30, 2022--Antibe Therapeutics Reports 2022 Year-End Results and Business Highlights